The Miracle of EM-X Therapy in Breast Cancer. Professor Khalida Usmani M.B.B.S, M.D, F.R.C.S Founder Cancer Research Foundation of Pakistan President,

Slides:

Advertisements

Similar presentations

TB 101 “Basic Facts on Tuberculosis”

Advertisements

†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.

Staff Oncologist, Mayo Clinic Arizona

Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.

Malignant Pleural Mesothelioma Post- Irradiation Treatment for Hodgkin’s Lymphoma Thea Price MD, R.V. Sooppan MD, Michael Walker MD Department of Thoracic.

ENT Gerard Kelly and general practice The Leeds Teaching

First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

Lung Cancer Wael Batobara. Lung Cancer Importance Risk Factors Classification & Manifestations Diagnosis Treatment.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

Breast Cancer Research in the Developing World Dr. Steven Narod Canada Research Chair in Breast Cancer Boston – November 2009.

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.

First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.

CRC-1 The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer Frances A. Shepherd, MD Scott Taylor Chair in Lung Cancer Research Princess Margaret.

The role of surgery in the management of mesothelioma Mr Martyn Carr Consultant Thoracic Surgeon Liverpool Heart and Chest Hospital.

Breast Cancer By George Rezk.

BREAST CANCER AWARENESS Sheraton Kuwait , Crystal Ballroom

BREAST CANCER OVERVIEW Polly Stephens, M.D.. BREAST ANATOMY.

Terminology of Neoplasms and Tumors  Neoplasm - new growth  Tumor - swelling or neoplasm  Leukemia - malignant disease of bone marrow  Hematoma -

Quang Truong Mr. Kashub 2nd Session

Resection For Lung Metastases M62 Coloproctology Course.

In the name of God Isfahan medical school Shahnaz Aram MD.

Stem Cells In Clinical Practice: STELLA Experience Manolo D’Arcangelo Department of Oncology Ospedale Civile di Livorno.

10 Minutes Talk 吳華席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.

Cancer Among Native Americans in Arizona and New Mexico Data Provided by Arizona Cancer Registry at the Arizona Department of Health Services and the New.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.

 General recommendations -adjuvant systemic therapy :with tamoxifen or multiple-chemotherapy agent :lower the incidence of recurrence by about 30% - in.

ER and PR Test Estrogen and Progesterone receptor status tests will show whether or not one or both of these hormones fuel the tumor Cancer that is hormone-sensitive.

Devin schonewolf Biology 2 mcgarvey

LUNG CANCER Johns Hopkins Hospital Lung Cancer, Non-Small Cell , All Cases n=1364 Analytic - Initially Diagnosed and/or received all.

By: Ashley Rodriguez, Yara parada, Briana Mendoza, Jackie Hernandez

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

Copyright © 2008 Delmar Learning. All rights reserved. Unit 47 Caring for the Patient with Cancer.

Recent and evolving trends in breast and colon cancer by Jeff Kolbasnik.

BREAST CANCER Oncology

Evidence Based Approach 5-Year Survival Rate for Breast Cancer Stage IV is 14% 2 to 5 percent become long-term survivors, possibly cured of their disease.

BREAST CANCER Breast cancer  Breast cancer is one of the commonest causes of death in many developed countries in middle-aged women, and is becoming.

GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.

3. How do you intend to resolve the issue?. Approach to the patient Assure patient’s safety! Talk the patient out of committing suicide – Remind him that.

Cell Biology & Cancer Unit Objective 1 Cancer types, incidence, pre-disposition, and risk factors Biomedical Technology.

JHH Prostate Cancer Prostate Cancer Cases Diagnosed 1999 – 2004 Analytic vs. Non-Analytic n=7776 * Analytic - Initially Diagnosed and/or received.

Effective Treatment of Malignant Pleural effusion by Minimal Invasive Thoracic Surgery: Thoracoscopic Talc Pleurodesis and Pleuroperitoneal shunt in 101.

CANCER CAUSES, REMEDIES & PREVENTION

According to the report, 22% of all cancer deaths are caused due to tobacco. So, it is extremely important to quit consuming tobacco products to prevent.

Lung Cancer Angel.

CASE 1: Management of metastatic disease in a resource-limited setting

Liver surgery for metachronous hepatic metastases with uterine body and uterine cervix origin – a single center experience Nicolae Bacalbasa (1), Irina.

Treatment of Oligometatic PNET Mets to Liver Following Resection

Dr Amit Gupta Associate Professor Dept Of Surgery

Bronchial Carcinoma Part 2

Respiratory Disorders

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Devin schonewolf Biology 2 mcgarvey

Intervista a Lucio Crinò

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Dr T P E Wells 13 July 2018 Breast SSG Bath

Satya Shanbhag Waikato Cardiothoracic Unit

Baselga J et al. SABCS 2009;Abstract 45.

General strategies of Cancer Treatment and evaluation of Response

Dr. Damjanovich László Dr. Fülöp Balázs

Presentation transcript:

The Miracle of EM-X Therapy in Breast Cancer. Professor Khalida Usmani M.B.B.S, M.D, F.R.C.S Founder Cancer Research Foundation of Pakistan President, World Institute of Ecology & Cancer (Asia Chair)

Risk Factors (Breast Cancer) Environmental Chemicals Pesticides Insecticides Air, Water & Food Pollution causing: Carcinogenesis Multiparity (Average of 5 Childrens) Malnourishment Prolonged Lactation (Average of 18 Months) Fibrocystic Disease of Breast

EMX - Antioxidant Increases T cell Population Immune Modulation Resistance to Disease

Dosage (EMX) Group I:5-10 ml/Day Group II:10-20ml/Day Group III:No EMX (Control)

Investigations & Diagnosis Mammography F.N.A True Cut N. Biopsy

Subjects & Methods Group I: EMX Treated from Day I Group II:Metastatic Disease EMX Given Group III:Locally Advanced, EMX Given Group IV:Control- No EMX

EM-X Therapy in Breast Cancer 1 st Phase : 1997 – nd Phase : 1999 – rd Phase : 2001 – th Phase :

Number of Cases

Present Study Age Range: Years (Majority of Patients) 35 – 45 Years Mostly Pre-menopausal Pregnant & Lactating - 14% Multiparous - 97 %

Improvement in Patients Percentage (P < 0.001)

Present Study EMX Started on Day 1 Before surgery No Mortality Due to CA Breast in g-I (Mastectomy performed by Professor Usmani)

Mortality within 2 years of group 2 & 3 EMX: 3 out of 55 Control: 4 out of 9

Post Operative Observations: No Undue Pain or Discomfort. Emotional Stability. Good Appetite. Improved Vitality. Discharged from Hospital in 4-5 Days.

Group II Metastatic disease patients Bone Secondaries. Pleural Effusion or Lung Mets. Liver Metastases.

Enhanced Work Status Improved Emotional Stability Improved Appetite Reduced Symptoms of Breathlessness & Pain EM-X Treated Patients

Conclusion Improved Immune Status Relief in Symptomatology Improved Work Status Emotional Well Being Improves Quality of Life Longer Survival Time in all Groups receiving EMX

Conclusion……..cont. When Combined with Standard Treatment (Chemo + DXT +H.T) No Pyogenic or Fungal Infections Longer Disease Free Interval Cure